SAGA Diagnostics® Announces Medicare Coverage for Pathlight™ MRD Test in Breast Cancer Across All Subtypes
Press Release Coverage marks a pivotal step in expanding access to ultra-sensitive MRD detection for breast cancer patients U.S. Medicare coverage decision reflects published, peer-reviewed clinical data demonstrating 100% sensitivity, 100% specificity, and a 13.7-month lead time versus standard-of-care clinical detection of recurrence across all subtypes and early stages of breast cancer MORRISVILLE, NC — […]
NeoCircle: circulating tumor DNA (ctDNA) dynamics during neoadjuvant chemotherapy predicts survival in primary breast cancer
Detecting ctDNA using personalized structural variants to forecast recurrence in localized soft tissue sarcoma (STS)
Tumor-informed ctDNA as an early predictive marker for relapse in advanced epithelial ovarian cancer
SAGA Diagnostics® Announces U.S. Commercial Launch of Pathlight™ at ASCO 2025, Setting a New Standard for Ultra-sensitive and Early MRD Detection
Press Release SAGA Diagnostics® Announces U.S. Commercial Launch of Pathlight™ at ASCO 2025, Setting a New Standard for Ultra-sensitive and Early MRD Detection Pathlight is a tumor-informed, multi-cancer MRD platform with its first indication in breast cancer Published, peer-reviewed clinical study demonstrates 100% sensitivity, 100% specificity, and a 13.7-month lead time to recurrence across all subtypes […]